Protective Effect and Possible Mechanisms of Artemisinin and Its Derivatives for Diabetic Nephropathy: A Systematic Review and Meta-Analysis in Animal Models

Background. Artemisinin and its derivatives have potential antidiabetic effects. There is no evaluation of reported studies in the literature on the treatment of diabetic nephropathy (DN), one of the commonest diabetic microangiopathies, with artemisinins. Here, we aimed to evaluate preclinical evid...

Full description

Saved in:
Bibliographic Details
Published in:Oxidative medicine and cellular longevity 2022, Vol.2022, p.5401760-20
Main Authors: Feng, Haoyue, Wu, Tingchao, Zhou, Qi, Li, Hui, Liu, Tianyi, Ma, Xitao, Yue, Rensong
Format: Article
Language:English
Subjects:
Animal research
Animals
Antidiabetics
Artemisinins - pharmacology
Artemisinins - therapeutic use
Bias
Diabetes
Diabetes Mellitus - drug therapy
Diabetic Nephropathies - drug therapy
Diabetic nephropathy
Drug dosages
Female
Humans
Kidney diseases
Laboratory animals
Male
Meta-analysis
Models, Animal
Proteinuria
Review
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3630-acd84ab8117c0863e0d1a955a89a34b1154d3f6c8bea1a465aee87bd2c629afa3
cites cdi_FETCH-LOGICAL-c3630-acd84ab8117c0863e0d1a955a89a34b1154d3f6c8bea1a465aee87bd2c629afa3
container_end_page 20
container_issue
container_start_page 5401760
container_title Oxidative medicine and cellular longevity
container_volume 2022
creator Feng, Haoyue
Wu, Tingchao
Zhou, Qi
Li, Hui
Liu, Tianyi
Ma, Xitao
Yue, Rensong
description Background. Artemisinin and its derivatives have potential antidiabetic effects. There is no evaluation of reported studies in the literature on the treatment of diabetic nephropathy (DN), one of the commonest diabetic microangiopathies, with artemisinins. Here, we aimed to evaluate preclinical evidence for the efficacy and possible mechanisms of artemisinins in reducing diabetic renal injury. Methods. We conducted an electronic literature search in fourteen databases from their inception to November 2021. All animal studies assessing the efficacy and safety of artemisinins in DN were included, regardless of publication or language. Overall, 178 articles were screened according to predefined inclusion and exclusion criteria. Finally, 18 eligible articles were included in this systematic review. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) risk-of-bias tool was used to assess the risk of bias in the included studies. The primary outcomes were kidney function, proteinuria, and renal pathology. Secondary endpoints included changes in fasting plasma glucose (FPG) levels, body weight, and relevant mechanisms. Results. Of the 18 included articles involving 418 animal models of DN, 1, 2, 6, and 9 used dihydroartemisinin, artemether, artesunate, and artemisinin, respectively. Overall, artemisinins reduced indicators of renal function, including blood urea nitrogen (P
doi_str_mv 10.1155/2022/5401760
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9073547</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2661485723</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3630-acd84ab8117c0863e0d1a955a89a34b1154d3f6c8bea1a465aee87bd2c629afa3</originalsourceid><addsrcrecordid>eNp9kUlvFDEQRlsIRBa4cUaWuCCFJl574YDUSgJEykDEcraq3dW0ox57sHsmmh_Df8WzMAIOnFxSPT9V1Zdlzxh9zZhS55xyfq4kZWVBH2THrJY8p3UtHx5qSo-ykxjvKC0El-xxdiSU4pXi7Dj7eRv8hGayKyRXfZ8qAq4jtz5G245IZmgGcDbOI_E9acKEcxuts26LXU-RXGKwK9gIIul9IJcWWpysIR9xMQS_gGlYvyEN-bKO6TNsOp9xZfF-a5jhBHnjYFxHG0nSNs7OYSQz3-EYn2SPehgjPt2_p9m3d1dfLz7kN5_eX180N7kRhaA5mK6S0FaMlYZWhUDaMaiVgqoGIdt0JtmJvjBVi8BAFgoQq7LtuCl4DT2I0-ztzrtYtnPsDLopwKgXIc0S1tqD1X93nB30d7_SNS2FkmUSvNwLgv-xxDjpdCaD4wgO_TJqXhRMVqrkIqEv_kHv_DKkC2wpWirJpEzUqx1lQooiYH8YhlG9yV1vctf73BP-_M8FDvDvoBNwtgMG6zq4t__X_QKsPLeW</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2660754144</pqid></control><display><type>article</type><title>Protective Effect and Possible Mechanisms of Artemisinin and Its Derivatives for Diabetic Nephropathy: A Systematic Review and Meta-Analysis in Animal Models</title><source>Open Access: Wiley-Blackwell Open Access Journals</source><source>Publicly Available Content (ProQuest)</source><creator>Feng, Haoyue ; Wu, Tingchao ; Zhou, Qi ; Li, Hui ; Liu, Tianyi ; Ma, Xitao ; Yue, Rensong</creator><contributor>Hassan, Imtaiyaz ; Imtaiyaz Hassan</contributor><creatorcontrib>Feng, Haoyue ; Wu, Tingchao ; Zhou, Qi ; Li, Hui ; Liu, Tianyi ; Ma, Xitao ; Yue, Rensong ; Hassan, Imtaiyaz ; Imtaiyaz Hassan</creatorcontrib><description>Background. Artemisinin and its derivatives have potential antidiabetic effects. There is no evaluation of reported studies in the literature on the treatment of diabetic nephropathy (DN), one of the commonest diabetic microangiopathies, with artemisinins. Here, we aimed to evaluate preclinical evidence for the efficacy and possible mechanisms of artemisinins in reducing diabetic renal injury. Methods. We conducted an electronic literature search in fourteen databases from their inception to November 2021. All animal studies assessing the efficacy and safety of artemisinins in DN were included, regardless of publication or language. Overall, 178 articles were screened according to predefined inclusion and exclusion criteria. Finally, 18 eligible articles were included in this systematic review. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) risk-of-bias tool was used to assess the risk of bias in the included studies. The primary outcomes were kidney function, proteinuria, and renal pathology. Secondary endpoints included changes in fasting plasma glucose (FPG) levels, body weight, and relevant mechanisms. Results. Of the 18 included articles involving 418 animal models of DN, 1, 2, 6, and 9 used dihydroartemisinin, artemether, artesunate, and artemisinin, respectively. Overall, artemisinins reduced indicators of renal function, including blood urea nitrogen (P&lt;0.00001), serum creatinine (P&lt;0.00001), and kidney index (P=0.0001) compared with control group treatment. Measurements of proteinuria (P&lt;0.00001), microalbuminuria (P&lt;0.05), and protein excretion (P=0.0002) suggested that treatment with artemisinins reduced protein loss in animals with DN. Artemisinins may lower blood glucose levels (P=0.01), but there is a risk of weight gain (P&lt;0.00001). Possible mechanisms of action of artemisinins include delaying renal fibrosis, reducing oxidative stress, and exerting antiapoptotic and anti-inflammatory effects. Conclusion. Available evidence suggests that artemisinins may be protective against renal injury secondary to diabetes in preclinical studies; however, high-quality and long-term trials are needed to reliably determine the balance of benefits and harms.</description><identifier>ISSN: 1942-0900</identifier><identifier>ISSN: 1942-0994</identifier><identifier>EISSN: 1942-0994</identifier><identifier>DOI: 10.1155/2022/5401760</identifier><identifier>PMID: 35528521</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>Animal research ; Animals ; Antidiabetics ; Artemisinins - pharmacology ; Artemisinins - therapeutic use ; Bias ; Diabetes ; Diabetes Mellitus - drug therapy ; Diabetic Nephropathies - drug therapy ; Diabetic nephropathy ; Drug dosages ; Female ; Humans ; Kidney diseases ; Laboratory animals ; Male ; Meta-analysis ; Models, Animal ; Proteinuria ; Review ; Systematic review</subject><ispartof>Oxidative medicine and cellular longevity, 2022, Vol.2022, p.5401760-20</ispartof><rights>Copyright © 2022 Haoyue Feng et al.</rights><rights>Copyright © 2022 Haoyue Feng et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2022 Haoyue Feng et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3630-acd84ab8117c0863e0d1a955a89a34b1154d3f6c8bea1a465aee87bd2c629afa3</citedby><cites>FETCH-LOGICAL-c3630-acd84ab8117c0863e0d1a955a89a34b1154d3f6c8bea1a465aee87bd2c629afa3</cites><orcidid>0000-0002-0571-6011 ; 0000-0003-2547-5945 ; 0000-0002-1231-3966 ; 0000-0002-5922-7264 ; 0000-0001-9663-1859 ; 0000-0003-2355-2687 ; 0000-0003-2790-4651</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2660754144/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2660754144?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,4009,25732,27902,27903,27904,36991,36992,44569,74872</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35528521$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Hassan, Imtaiyaz</contributor><contributor>Imtaiyaz Hassan</contributor><creatorcontrib>Feng, Haoyue</creatorcontrib><creatorcontrib>Wu, Tingchao</creatorcontrib><creatorcontrib>Zhou, Qi</creatorcontrib><creatorcontrib>Li, Hui</creatorcontrib><creatorcontrib>Liu, Tianyi</creatorcontrib><creatorcontrib>Ma, Xitao</creatorcontrib><creatorcontrib>Yue, Rensong</creatorcontrib><title>Protective Effect and Possible Mechanisms of Artemisinin and Its Derivatives for Diabetic Nephropathy: A Systematic Review and Meta-Analysis in Animal Models</title><title>Oxidative medicine and cellular longevity</title><addtitle>Oxid Med Cell Longev</addtitle><description>Background. Artemisinin and its derivatives have potential antidiabetic effects. There is no evaluation of reported studies in the literature on the treatment of diabetic nephropathy (DN), one of the commonest diabetic microangiopathies, with artemisinins. Here, we aimed to evaluate preclinical evidence for the efficacy and possible mechanisms of artemisinins in reducing diabetic renal injury. Methods. We conducted an electronic literature search in fourteen databases from their inception to November 2021. All animal studies assessing the efficacy and safety of artemisinins in DN were included, regardless of publication or language. Overall, 178 articles were screened according to predefined inclusion and exclusion criteria. Finally, 18 eligible articles were included in this systematic review. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) risk-of-bias tool was used to assess the risk of bias in the included studies. The primary outcomes were kidney function, proteinuria, and renal pathology. Secondary endpoints included changes in fasting plasma glucose (FPG) levels, body weight, and relevant mechanisms. Results. Of the 18 included articles involving 418 animal models of DN, 1, 2, 6, and 9 used dihydroartemisinin, artemether, artesunate, and artemisinin, respectively. Overall, artemisinins reduced indicators of renal function, including blood urea nitrogen (P&lt;0.00001), serum creatinine (P&lt;0.00001), and kidney index (P=0.0001) compared with control group treatment. Measurements of proteinuria (P&lt;0.00001), microalbuminuria (P&lt;0.05), and protein excretion (P=0.0002) suggested that treatment with artemisinins reduced protein loss in animals with DN. Artemisinins may lower blood glucose levels (P=0.01), but there is a risk of weight gain (P&lt;0.00001). Possible mechanisms of action of artemisinins include delaying renal fibrosis, reducing oxidative stress, and exerting antiapoptotic and anti-inflammatory effects. Conclusion. Available evidence suggests that artemisinins may be protective against renal injury secondary to diabetes in preclinical studies; however, high-quality and long-term trials are needed to reliably determine the balance of benefits and harms.</description><subject>Animal research</subject><subject>Animals</subject><subject>Antidiabetics</subject><subject>Artemisinins - pharmacology</subject><subject>Artemisinins - therapeutic use</subject><subject>Bias</subject><subject>Diabetes</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Diabetic Nephropathies - drug therapy</subject><subject>Diabetic nephropathy</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Humans</subject><subject>Kidney diseases</subject><subject>Laboratory animals</subject><subject>Male</subject><subject>Meta-analysis</subject><subject>Models, Animal</subject><subject>Proteinuria</subject><subject>Review</subject><subject>Systematic review</subject><issn>1942-0900</issn><issn>1942-0994</issn><issn>1942-0994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kUlvFDEQRlsIRBa4cUaWuCCFJl574YDUSgJEykDEcraq3dW0ox57sHsmmh_Df8WzMAIOnFxSPT9V1Zdlzxh9zZhS55xyfq4kZWVBH2THrJY8p3UtHx5qSo-ykxjvKC0El-xxdiSU4pXi7Dj7eRv8hGayKyRXfZ8qAq4jtz5G245IZmgGcDbOI_E9acKEcxuts26LXU-RXGKwK9gIIul9IJcWWpysIR9xMQS_gGlYvyEN-bKO6TNsOp9xZfF-a5jhBHnjYFxHG0nSNs7OYSQz3-EYn2SPehgjPt2_p9m3d1dfLz7kN5_eX180N7kRhaA5mK6S0FaMlYZWhUDaMaiVgqoGIdt0JtmJvjBVi8BAFgoQq7LtuCl4DT2I0-ztzrtYtnPsDLopwKgXIc0S1tqD1X93nB30d7_SNS2FkmUSvNwLgv-xxDjpdCaD4wgO_TJqXhRMVqrkIqEv_kHv_DKkC2wpWirJpEzUqx1lQooiYH8YhlG9yV1vctf73BP-_M8FDvDvoBNwtgMG6zq4t__X_QKsPLeW</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Feng, Haoyue</creator><creator>Wu, Tingchao</creator><creator>Zhou, Qi</creator><creator>Li, Hui</creator><creator>Liu, Tianyi</creator><creator>Ma, Xitao</creator><creator>Yue, Rensong</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0571-6011</orcidid><orcidid>https://orcid.org/0000-0003-2547-5945</orcidid><orcidid>https://orcid.org/0000-0002-1231-3966</orcidid><orcidid>https://orcid.org/0000-0002-5922-7264</orcidid><orcidid>https://orcid.org/0000-0001-9663-1859</orcidid><orcidid>https://orcid.org/0000-0003-2355-2687</orcidid><orcidid>https://orcid.org/0000-0003-2790-4651</orcidid></search><sort><creationdate>2022</creationdate><title>Protective Effect and Possible Mechanisms of Artemisinin and Its Derivatives for Diabetic Nephropathy: A Systematic Review and Meta-Analysis in Animal Models</title><author>Feng, Haoyue ; Wu, Tingchao ; Zhou, Qi ; Li, Hui ; Liu, Tianyi ; Ma, Xitao ; Yue, Rensong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3630-acd84ab8117c0863e0d1a955a89a34b1154d3f6c8bea1a465aee87bd2c629afa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animal research</topic><topic>Animals</topic><topic>Antidiabetics</topic><topic>Artemisinins - pharmacology</topic><topic>Artemisinins - therapeutic use</topic><topic>Bias</topic><topic>Diabetes</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Diabetic Nephropathies - drug therapy</topic><topic>Diabetic nephropathy</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Humans</topic><topic>Kidney diseases</topic><topic>Laboratory animals</topic><topic>Male</topic><topic>Meta-analysis</topic><topic>Models, Animal</topic><topic>Proteinuria</topic><topic>Review</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Feng, Haoyue</creatorcontrib><creatorcontrib>Wu, Tingchao</creatorcontrib><creatorcontrib>Zhou, Qi</creatorcontrib><creatorcontrib>Li, Hui</creatorcontrib><creatorcontrib>Liu, Tianyi</creatorcontrib><creatorcontrib>Ma, Xitao</creatorcontrib><creatorcontrib>Yue, Rensong</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oxidative medicine and cellular longevity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Feng, Haoyue</au><au>Wu, Tingchao</au><au>Zhou, Qi</au><au>Li, Hui</au><au>Liu, Tianyi</au><au>Ma, Xitao</au><au>Yue, Rensong</au><au>Hassan, Imtaiyaz</au><au>Imtaiyaz Hassan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protective Effect and Possible Mechanisms of Artemisinin and Its Derivatives for Diabetic Nephropathy: A Systematic Review and Meta-Analysis in Animal Models</atitle><jtitle>Oxidative medicine and cellular longevity</jtitle><addtitle>Oxid Med Cell Longev</addtitle><date>2022</date><risdate>2022</risdate><volume>2022</volume><spage>5401760</spage><epage>20</epage><pages>5401760-20</pages><issn>1942-0900</issn><issn>1942-0994</issn><eissn>1942-0994</eissn><abstract>Background. Artemisinin and its derivatives have potential antidiabetic effects. There is no evaluation of reported studies in the literature on the treatment of diabetic nephropathy (DN), one of the commonest diabetic microangiopathies, with artemisinins. Here, we aimed to evaluate preclinical evidence for the efficacy and possible mechanisms of artemisinins in reducing diabetic renal injury. Methods. We conducted an electronic literature search in fourteen databases from their inception to November 2021. All animal studies assessing the efficacy and safety of artemisinins in DN were included, regardless of publication or language. Overall, 178 articles were screened according to predefined inclusion and exclusion criteria. Finally, 18 eligible articles were included in this systematic review. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) risk-of-bias tool was used to assess the risk of bias in the included studies. The primary outcomes were kidney function, proteinuria, and renal pathology. Secondary endpoints included changes in fasting plasma glucose (FPG) levels, body weight, and relevant mechanisms. Results. Of the 18 included articles involving 418 animal models of DN, 1, 2, 6, and 9 used dihydroartemisinin, artemether, artesunate, and artemisinin, respectively. Overall, artemisinins reduced indicators of renal function, including blood urea nitrogen (P&lt;0.00001), serum creatinine (P&lt;0.00001), and kidney index (P=0.0001) compared with control group treatment. Measurements of proteinuria (P&lt;0.00001), microalbuminuria (P&lt;0.05), and protein excretion (P=0.0002) suggested that treatment with artemisinins reduced protein loss in animals with DN. Artemisinins may lower blood glucose levels (P=0.01), but there is a risk of weight gain (P&lt;0.00001). Possible mechanisms of action of artemisinins include delaying renal fibrosis, reducing oxidative stress, and exerting antiapoptotic and anti-inflammatory effects. Conclusion. Available evidence suggests that artemisinins may be protective against renal injury secondary to diabetes in preclinical studies; however, high-quality and long-term trials are needed to reliably determine the balance of benefits and harms.</abstract><cop>United States</cop><pub>Hindawi</pub><pmid>35528521</pmid><doi>10.1155/2022/5401760</doi><tpages>20</tpages><orcidid>https://orcid.org/0000-0002-0571-6011</orcidid><orcidid>https://orcid.org/0000-0003-2547-5945</orcidid><orcidid>https://orcid.org/0000-0002-1231-3966</orcidid><orcidid>https://orcid.org/0000-0002-5922-7264</orcidid><orcidid>https://orcid.org/0000-0001-9663-1859</orcidid><orcidid>https://orcid.org/0000-0003-2355-2687</orcidid><orcidid>https://orcid.org/0000-0003-2790-4651</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1942-0900
ispartof Oxidative medicine and cellular longevity, 2022, Vol.2022, p.5401760-20
issn 1942-0900
1942-0994
1942-0994
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9073547
source Open Access: Wiley-Blackwell Open Access Journals; Publicly Available Content (ProQuest)
subjects Animal research
Animals
Antidiabetics
Artemisinins - pharmacology
Artemisinins - therapeutic use
Bias
Diabetes
Diabetes Mellitus - drug therapy
Diabetic Nephropathies - drug therapy
Diabetic nephropathy
Drug dosages
Female
Humans
Kidney diseases
Laboratory animals
Male
Meta-analysis
Models, Animal
Proteinuria
Review
Systematic review
title Protective Effect and Possible Mechanisms of Artemisinin and Its Derivatives for Diabetic Nephropathy: A Systematic Review and Meta-Analysis in Animal Models
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T09%3A28%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protective%20Effect%20and%20Possible%20Mechanisms%20of%20Artemisinin%20and%20Its%20Derivatives%20for%20Diabetic%20Nephropathy:%20A%20Systematic%20Review%20and%20Meta-Analysis%20in%20Animal%20Models&rft.jtitle=Oxidative%20medicine%20and%20cellular%20longevity&rft.au=Feng,%20Haoyue&rft.date=2022&rft.volume=2022&rft.spage=5401760&rft.epage=20&rft.pages=5401760-20&rft.issn=1942-0900&rft.eissn=1942-0994&rft_id=info:doi/10.1155/2022/5401760&rft_dat=%3Cproquest_pubme%3E2661485723%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3630-acd84ab8117c0863e0d1a955a89a34b1154d3f6c8bea1a465aee87bd2c629afa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2660754144&rft_id=info:pmid/35528521&rfr_iscdi=true